Cboe Global Markets is developing a new, regulated options product featuring a simplified 'all-or-none' payout structure, targeting retail investors drawn to event-style trading. The move comes as U.S. regulators work to define rules for prediction markets and event contracts.
While major indices waver, a select group of undervalued small-cap companies is attracting attention from those who know them best—their own executives. We examine three firms where recent insider buying hints at underlying value, from UK pubs to Canadian tech and U.S. manufactured housing.
The recent Symposium on International Automotive Technology indicates India's electric vehicle market is maturing, with future launches focusing on engineering discipline, safety compliance, and platform-based scalability over rapid, incentive-driven rollouts.
Amidst a volatile tech sector, one cybersecurity stalwart stands out for its rare consensus among Wall Street analysts. While not the flashiest name, Check Point Software's disciplined strategy and robust margins position it as a compelling value proposition for 2026.
Despite posting robust quarterly results and a booming AI business, ServiceNow's stock has stumbled amid a broader sector sell-off. The disconnect between operational strength and share price performance is raising questions about market sentiment and long-term value.
The professional services firm elevates seven senior professionals to partner across key advisory divisions, a strategic move aligned with its ambitious plan to add 160 partners within two years.
Benchmark maintains a Buy rating and $62 price target for Matador Resources (MTDR), anticipating a midstream asset sale this year to fuel growth and reduce debt, even as it trims Q4 EBITDA estimates on commodity price volatility.
RBC Capital Markets has increased its price target for APA Corporation, citing improved operational stability and better-than-expected cost reductions. The independent energy producer is now ahead of schedule on its savings goal.
Bank of America Securities has named Brazilian mining giant Vale S.A. (VALE) a top investment pick for 2026, raising its price target to $17 following a year of exceptional performance that saw shares climb 47%. Analysts cite operational strength, robust cash flow, and de-risking efforts as key drivers.
Following management meetings at the ICR Conference, UBS reaffirms its Buy rating and $160 price target for ANF, citing resilient brand fundamentals and a path to sustained earnings growth despite near-term challenges for the Hollister brand.
Analysts at Piper Sandler project that addressing long-standing vehicle quality issues could unlock nearly $3 billion in additional operating profit for Ford by 2026, even as the automaker trades at a depressed valuation.
AstraZeneca has entered a strategic collaboration with China's CSPC Pharmaceutical Group to co-develop and commercialize a portfolio of next-generation therapies for obesity and type 2 diabetes, significantly expanding its weight management pipeline.
Evercore ISI has upgraded Cisco Systems (CSCO) to Outperform, raising its price target to $100. The firm cites a confluence of AI momentum, a critical campus refresh cycle, and margin expansion as key drivers for sustained growth.
Merck & Co. declares a steady quarterly dividend as analysts from Cantor Fitzgerald and Citi raise price targets, citing a 'beatable' earnings outlook and reduced policy risks for the coming year, though the stock's performance remains tethered to late-stage pipeline developments.
Philip Morris International navigates a pivotal FDA review for its ZYN nicotine pouches, aiming for a marketing advantage in the smoke-free future. Wall Street analysts offer mixed ratings, highlighting the competitive pressures and strategic shifts defining the tobacco giant's investment profile.
As AbbVie navigates a pivotal year for its key drugs and pipeline, Wall Street analysts are offering mixed signals. While Citi adopts a cautious stance, Berenberg raises its price target, highlighting the contrasting perspectives on the pharmaceutical giant's future.
Wall Street analysts offer mixed signals on Procter & Gamble (NYSE: PG), with recent rating changes highlighting concerns over subdued growth prospects despite its reputation as a defensive staple.
Bank of America has increased its price target for healthcare giant Johnson & Johnson to $227, highlighting its defensive investment profile and growth in MedTech, while downplaying the financial impact of ongoing talc litigation.
Walmart Inc. (WMT) is making a significant push into the health and wellness sector with major investments in pharmacy staffing and services, coinciding with a bullish price target upgrade from UBS. The retail giant's strategic moves come as competition in the pharmacy delivery space intensifies.
Pharmaceutical giant Eli Lilly announces a major investment in a new Lehigh Valley manufacturing site, set to create hundreds of jobs and bolster U.S. production capacity for its in-demand injectable therapies, including weight-loss drugs.
